1032827-20-5

Basic information

• Product Name: 6-methoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol
• Synonyms: 6-methoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol
• CAS NO: 1032827-20-5
• Molecular Weight: 283.37
• Mol File: 1032827-20-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 6-methoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-methoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol(1032827-20-5)
• EPA Substance Registry System: 6-methoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol(1032827-20-5)

Safety Data

• Hazardous Substances Data: 1032827-20-5(Hazardous Substances Data)

Upstream product

• 4602-73-7 3,4-dihydro-7-hydroxy-6-methoxy-isoquinoline 
• 103-63-9 1-phenyl-2-bromoethane 

Downstream Products

• 1426260-32-3 6-methoxy-8-(2-methoxyphenyl)-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-33-4 6-methoxy-8-(4-methoxyphenyl)-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-47-0 8-(3,5-dimethoxyphenyl)-6-methoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-48-1 8-(2,3-dimethoxyphenyl)-6-methoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-91-4 8-bromo-6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline 
• 1426260-95-8 8-(2-fluorophenyl)-6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline 
• 1426260-35-6 6-methoxy-8-(3,4,5-trimethoxyphenyl)-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-34-5 6-methoxy-8-(3-methoxyphenyl)-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-40-3 8-(2-cyanophenyl)-6-methoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-38-9 6-methoxy-8-(4-methylthiophenyl)-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-37-8 6-methoxy-8-(2-methylthiophenyl)-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol 

Relevant articles and documents

8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME

A series of 8-phenyl-isoquinoline derivatives (I) exhibit high binding affinity to 5-HT7 receptor (5-HT7R) and demonstrate potent antinociceptive activity in two animal models for Irritable Bowel Syndrome (IBS) by intraperitoneal injection (i.p.) or by oral administration (p.o.). These 5-HT7 receptor antagonists are a new class of therapeutic agents for the treatment of IBS.